MicroRNA-492 is processed from the keratin 19 gene and up-regulated in metastatic hepatoblastoma

Hepatology

Volumn 53, Issue 3, 2011, Pages 833-842

  von Frowein, Julia ^a   Pagel, Philipp ^b   Kappler, Roland ^a   von Schweinitz, Dietrich ^a   Roscher, Adelbert ^a   Schmid, Irene ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; BILE ACID COENZYME A:AMINO ACID N ACYLTRANSFERASE; CYTOKERATIN 19; MICRORNA; MICRORNA 492; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; CELL CLONING; COMPUTER ANALYSIS; CONTROLLED STUDY; GENE FUNCTION; GENE OVEREXPRESSION; GENE SEQUENCE; HEPATOBLASTOMA; HUMAN; HUMAN TISSUE; METASTASIS; NUCLEOTIDE SEQUENCE; ONCOGENE; PLEOMORPHIC ADENOMA GENE 1; PRIORITY JOURNAL; PROTEIN INTERACTION; RNA INTERFERENCE; STABLE EXPRESSION; TUMOR GROWTH; UPREGULATION;

CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; HEPATOBLASTOMA; HUMANS; INFANT; KERATIN-19; LIVER NEOPLASMS; MALE; MICRORNAS;

EID: 79952212867     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24125     Document Type: Article

References (41)

1. Weinberg AG, Finegold MJ. Primary hepatic tumors of childhood. Hum Pathol 1983; 14: 512-537.
2. Ishak KG, Glunz PR. Hepatoblastoma and hepatocarcinoma in infancy and childhood. Report of 47 cases. Cancer 1967; 20: 396-422.
3. Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 2009; 361: 1662-1670.
4. Fuchs J, Rydzynski J, von Schweinitz D, Bode U, Hecker H, Weinel P, et al. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 2002; 95: 172-182.
5. Perilongo G, Shafford E, Maibach R, Aronson D, Brugieres L, Brock P, et al. Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology-SIOPEL 2. Eur J Cancer 2004; 40: 411-421.
6. Jeng YM, Wu MZ, Mao TL, Chang MH, Hsu HC. Somatic mutations of beta-catenin play a crucial role in the tumorigenesis of sporadic hepatoblastoma. Cancer Lett 2000; 152: 45-51.
7. Koch A, Denkhaus D, Albrecht S, Leuschner I, von Schweinitz D, Pietsch T. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 1999; 59: 269-273.
8. Hartmann W, Waha A, Koch A, Goodyer CG, Albrecht S, von Schweinitz D, et al. p57(KIP2) is not mutated in hepatoblastoma but shows increased transcriptional activity in a comparative analysis of the three imprinted genes p57(KIP2), IGF2, and H19. Am J Pathol 2000; 157: 1393-1403.
9. Li X, Adam G, Cui H, Sandstedt B, Ohlsson R, Ekstrom TJ. Expression, promoter usage and parental imprinting status of insulin-like growth factor II (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting. Oncogene 1995; 11: 221-229.
10. Zatkova A, Rouillard JM, Hartmann W, Lamb BJ, Kuick R, Eckart M, et al. Amplification and overexpression of the IGF2 regulator PLAG1 in hepatoblastoma. Genes Chromosomes Cancer 2004; 39: 126-137.
11. Van Dyck F, Declercq J, Braem CV, Van de Ven WJ. PLAG1, the prototype of the PLAG gene family: versatility in tumour development (review). Int J Oncol 2007; 30: 765-774.
12. Voz ML, Agten NS, Van de Ven WJ, Kas K. PLAG1, the main translocation target in pleomorphic adenoma of the salivary glands, is a positive regulator of IGF-II. Cancer Res 2000; 60: 106-113.
13. Voz ML, Mathys J, Hensen K, Pendeville H, Van V, et al. Microarray screening for target genes of the proto-oncogene PLAG1. Oncogene 2004; 23: 179-191.
14. Kas K, Voz ML, Hensen K, Meyen E, Van de Ven WJ. Transcriptional activation capacity of the novel PLAG family of zinc finger proteins. J Biol Chem 1998; 273: 23026-23032.
15. Kamohara Y, Haraguchi N, Mimori K, Tanaka F, Inoue H, Mori M, et al. The search for cancer stem cells in hepatocellular carcinoma. Surgery 2008; 144: 119-124.
16. Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, et al. From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics 2004; 3: 73-81.
17. Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J, et al. The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 2006; 49: 138-151.
18. Cairo S, Armengol C, de Reynies A, Wei Y, Thomas E, Renard CA, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008; 14: 471-484.
19. Osada H, Takahashi T. MicroRNAs in biological processes and carcinogenesis. Carcinogenesis 2007; 28: 2-12.
20. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004; 5: 522-531.
21. Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005; 15: 563-568.
22. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of mammalian microRNA host genes and transcription units. Genome Res 2004; 14: 1902-1910.
23. Wei JS, Johansson P, Chen QR, Song YK, Durinck S, Wen X, et al. microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clin Cancer Res 2009; 15: 5560-5568.
24. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. HEPATOLOGY 2008; 47: 897-907.
25. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25: 2537-2545.
26. R Development Core Team. R: A Language and Environment for Statistical Computing Vienna, Austria: R Foundation for Statistical Computing; 2008.
27. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
28. Smyth GK. Limma: Linear Models for Microarray Data. New York: Springer; 2005.
29. Devor EJ. Primate microRNAs miR-220 and miR-492 lie within processed pseudogenes. J Hered 2006; 97: 186-190.
30. Das S. Evolutionary origin and genomic organization of micro-RNA genes in immunoglobulin lambda variable region gene family. Mol Biol Evol 2009; 26: 1179-1189.
31. Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, et al. Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. HEPATOLOGY 2009; 50: 472-480.
32. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of microRNA processing by p53. Nature 2009; 460: 529-533.
33. van Sprundel RG, van den Ingh TS, Desmet VJ, Katoonizadeh A, Penning LC, Rothuizen J, et al. Keratin 19 marks poor differentiation and a more aggressive behaviour in canine and human hepatocellular tumours. Comp Hepatol 2010; 9: 4.
34. Endo T, Yoshikawa M, Ebara M, Kato K, Sunaga M, Fukuda H, et al. Immunohistochemical metallothionein expression in hepatocellular carcinoma: relation to tumor progression and chemoresistance to platinum agents. J Gastroenterol 2004; 39: 1196-1201.
35. Tao X, Zheng JM, Xu AM, Chen XF, Zhang SH. Downregulated expression of metallothionein and its clinicopathological significance in hepatocellular carcinoma. Hepatol Res 2007; 37: 820-827.
36. Noel ES, Reis MD, Arain Z, Ober EA. Analysis of the Albumin/alpha-Fetoprotein/Afamin/Group specific component gene family in the context of zebrafish liver differentiation. Gene Expr Patterns 2010; 10: 237-243.
37. Magrelli A, Azzalin G, Salvatore M, Viganotti M, Tosto F, Colombo T, et al. Altered microRNA expression patterns in hepatoblastoma patients. Transl Oncol 2009; 2: 157-163.
38. Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjot L, et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008; 68: 6416-6424.
39. Furutani M, Arii S, Higashitsuji H, Mise M, Niwano M, Harada T, et al. kan-1 (bile acid CoA:amino acid N-acyltransferase) messenger RNA as a novel predictive indicator for prognosis of hepatocellular carcinoma patients after partial hepatectomy. HEPATOLOGY 1996; 24: 1441-1445.
40. Pellicoro A, van den Heuvel FA, Geuken M, Moshage H, Jansen PL, Faber KN. Human and rat bile acid-CoA:amino acid N-acyltransferase are liver-specific peroxisomal enzymes: implications for intracellular bile salt transport. HEPATOLOGY 2007; 45: 340-348.
41. Kubo K, Honda H, Honda H, Sannomiya K, Aying Y, Mei W, et al. Histochemical and immunohistochemical investigation of guanase and nedasin in human tissues. J Med Invest 2006; 53: 264-270.